Kyverna Therapeutics (KYTX) Net Cash Flow (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Net Cash Flow data on file, last reported at -$91.9 million in Q1 2026.

• Quarterly Net Cash Flow fell 131.27% year-over-year to -$91.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.7 million (up 85.26% YoY) and the FY2025 annual result came in at $27.5 million, down 55.64% from the prior year.
• Net Cash Flow eased to -$91.9 million in Q1 2026, from $89.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $189.6 million in Q1 2024 to a low of -$92.7 million in Q2 2024.
• A 4-year average of -$425538.5 and a median of -$8.1 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 9137.46% in 2024, down 779.06% in 2024.
• Tracing KYTX's Net Cash Flow over 4 years: stood at $11.7 million in 2023, then plunged by 168.93% to -$8.1 million in 2024, then surged by 1216.72% to $89.9 million in 2025, then plunged by 202.18% to -$91.9 million in 2026.
• The last three Net Cash Flow figures came in at -$91.9 million (Q1 2026), $89.9 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.